High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis

• DOI: 10.3389/fimmu.2023.1160710
• Publication Date: 2023-04-20T14:42:37Z
• Authors: Ao Wang; Yuan Zhou; Yang Luo; Yingxia Gao; Jingsi Chen; Wei Li; Xiaoyan Luo; Xu Yao
• Keywords: Dupilumab

Background The real-world experience of dupilumab in Chinese is limited, and the initial loading dose has not yet been deeply explored patients aged <6 years. Objective To explore efficacy safety with moderate-to-severe atopic dermatitis investigate effect higher for disease control Methods A total 155 were divided into three groups according to age: years, 6-11 >11 Among 37 received a high 300 mg body weight <15kg or 600 ≥15kg, another standard 200 ≥15kg. Multiple physicians patient-reported outcome measures evaluated at baseline 2, 4, 6, 8, 12, 16 weeks after treatment. Results proportion showing an improvement ≥75% Eczema Area Severity Index was 68.0% (17/25), 76.9% (10/13), 62.5% (25/40) <6, 6-11, years groups, respectively, week 16. After increasing dose, 69.6% (16/23) achieved 4-point Pruritus Numerical Rating Scale compared 23.5% (8/34) receiving ( P < 0.001). Obesity (odds ratio=0.12, 95% confidence interval: 0.02-0.70) predictive poor response treatment, while female ratio=3.94, 1.26-12.31) predicted good change serum C-C motif ligand 17(CCL17/TARC) could reflect r = 0.53, 0.002 EASI) among <18 No major adverse events reported during Conclusions Dupilumab effective well-tolerated dermatitis. increased helped achieve rapid pruritus